Login to Your Account



Washington Roundup

Possible Quad Pricing Raises Congressional Eyebrows

By Mari Serebrov
Washington Editor

Wednesday, August 15, 2012
With the PDUFA date for Gilead Sciences Inc.'s Quad less than a fortnight off, the company is coming under congressional pressure to reduce the expected price of what is likely to be the next big HIV therapy.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription